DOCK8-AS1: A Potential Drug Target and Biomarker (G157983)

Target Name: DOCK8-AS1

NCBI ID: G157983

DOCK8-AS1

DOCK8-AS1: A Potential Drug Target and Biomarker

DOCK8 (Disk-in-Chain) is a gene that encodes a protein involved in intracellular signaling pathways, including cell adhesion, migration, and invasion. AS1 (antibody-secreting unit) is a gene that encodes an antibody that can interact with DOCK8 and regulate its activity. In this article, we discuss the potential implications of DOCK8-AS1 as a drug target and biomarker.

DOCK8-AS1: Structure and Function

The DOCK8 gene encodes a protein that consists of 211 amino acids. The protein has a molecular weight of 20.9 kDa and a pre-protein N-terminal extension of 24 amino acids. The protein has a single transmembrane segment and a cytoplasmic tail. DOCK8-AS1 is a 193 amino acid long piece of RNA that is derived from the coding protein. It has a 5'-end that is 3' to the right of the start codon and a 3'-end that is 5' to the left.

The DOCK8 protein is involved in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to play a role in the regulation of cell cycle progression, apoptosis, and cell survival. DOCK8 has also been shown to interact with various signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival.

The AS1 gene encodes an antibody that can interact with DOCK8. The AS1 protein has a molecular weight of 170 kDa and consists of two heavy chains and two light chains. The antibody has a single transmembrane segment and a cytoplasmic tail.

DOCK8-AS1 Interaction

The DOCK8 protein is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. The AS1 protein has been shown to interact with DOCK8 and regulate its activity. This interaction between DOCK8 and AS1 has been shown to play a role in the regulation of cellular processes, including cell adhesion and migration.

In cell adhesion, DOCK8 is involved in the regulation of the formation of tight junctions, which are a type of cell-cell adhesion barrier. tight junctions are responsible for maintaining the integrity of the endosomal system and are involved in the delivery of various proteins to the cell surface. DOCK8 has been shown to interact with the protein transmembrane protein (TMP), which is involved in the formation of tight junctions.

In migration, DOCK8 is involved in the regulation of cell migration. DOCK8 has been shown to interact with the protein FAK, which is involved in the regulation of cell adhesion and migration.

In invasion, DOCK8 is involved in the regulation of cell invasion. DOCK8 has been shown to interact with the protein CDN1, which is involved in the regulation of cell invasion.

DOCK8-AS1 as a Drug Target

The potential implications of DOCK8-AS1 as a drug target are significant. The regulation of DOCK8 by AS1 is a potential target for small molecules that can inhibit AS1 activity and disrupt its ability to interact with DOCK8. This could lead to the inhibition of cellular processes, including cell adhesion, migration, and invasion.

DOCK8 has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and invasion. The regulation of DOCK8 by AS1 is a potential target for small molecules that can inhibit AS1 activity and disrupt its ability to interact with DOCK8. This could lead to the inhibition of cellular processes, including cell adhesion, migration, and invasion.

DOCK8-AS1 as a Biomarker

DOCK8-AS1 can also be used as a biomarker for various diseases. For

Protein Name: DOCK8 Antisense RNA 1

The "DOCK8-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOCK8-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets